Navigation Links
Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
Date:6/8/2009

, Weston Park Hospital, Shefield.

About Pixantrone

Pixantrone (BBR 2778), is a novel major groove binder with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_news.htm

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pi
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
3. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
4. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
5. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
6. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
7. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
8. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
9. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
10. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
11. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 1, 2014  PTC Therapeutics, Inc. (NASDAQ: ... it approved non-statutory stock options to purchase an aggregate ... new employees. The awards were made pursuant to the ... new hires, employment compensation. The inducement grants ... 2014 and are being made as an inducement material ...
(Date:8/1/2014)... , Aug. 1, 2014  With monumental health reform ... speak a second language. Clinical efficacy is no longer ... under the ACA like PCORI are directing roughly $1 ... of new entities and environments, the federal healthcare ecosystem ... new language of outcomes and managed markets to the ...
(Date:8/1/2014)... and NEW YORK , ... VRX) and Pershing Square Capital Management, L.P. today responded ... Inc. (NYSE: AGN ) in California.  The ... regarding the tender offer rules.  Allergan,s ... to interfere with shareholders, efforts to call a special ...
Breaking Medicine Technology:PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 2Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 4Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 5Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 6
... International, Inc. (NYSE: VRX and ... to acquire certain assets from University Medical Pharmaceuticals ... products, for approximately $64 million plus potential milestones ... Medical,s main brand is AcneFree, a leading retail ...
... 3, 2012 New Report Added in ... and Forecasts, Worldwide, 2012 to 2018 ... Worldwide markets are poised to achieve significant growth as the ... to patients with chronic disease, decreasing hospitalizations and visits to ...
Cached Medicine Technology:Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical 2ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report 2ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report 3ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report 4ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report 5ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report 6ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report 7ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report 8
(Date:8/1/2014)... (HealthDay News) -- Almost 140 people die every ... the United States. But there are several ... Gardner, injury prevention coordinator at Cincinnati Children,s Hospital ... a medical center news release. "As families ... it,s important for parents and children to go ...
(Date:8/1/2014)... Vegas, NV (PRWEB) August 01, 2014 ... and opportunities for independent community pharmacies. At ThoughtSpot ... pharmacists are equipped with practices and resources to ... Session, AmerisourceBergen leaders focused on critical issues to ... learn, optimize and grow. , ThoughtSpot show ...
(Date:8/1/2014)... DC (PRWEB) August 01, 2014 ... Thompson (D-CA), Gregg Harper (R-MS), and Peter Welch ... 5380, the Medicare Telehealth Parity Act of 2014, ... fully support this effort to improve healthcare access ... chief executive officer of ATA. "These cost-saving provisions ...
(Date:8/1/2014)... On Monday, June 30th, the Quirk Healthcare ... San Francisco, CA. Now in its fourth year, the ... Square hotel. , “We are excited about returning to ... ACA compliance issues,” Quirk Healthcare Foundation Executive Director, Ben ... guidance with NextGen implementation and use, electronic records documentation ...
(Date:8/1/2014)... 1, 2014 (HealthDay News) -- Although many parents worry about ... a common choking hazard: food. Such was the ... cough after eating a handful of nuts. "At the ... if the coughing was related to his illness or choking," ... cold. A cashew had become lodged in his windpipe and ...
Breaking Medicine News(10 mins):Health News:Expert Offers School Bus Safety Tips 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2Health News:Food Is a Common Choking Hazard for Kids, Doctor Says 2
... a severe stroke generally improves the patients, lives and ... neurologists at the University of Rochester Medical Center. , ... perspective a decision that is nearly always painful and ... aggressive surgery after a catastrophic stroke is worth it. ...
... Improved patient-oriented research in Europe will benefit European citizens ... of scientific discoveries from the laboratory bench to the ... world this effort will be of great importance for ... of society as a whole. , To achieve ...
... will affect more than 78 million U.S. baby ... can resolve their vision needs to avoid readers.ROCHESTER, ... of the #1 multifocal lens design, has launched ... of raising U.S. awareness of presbyopia and multifocal ...
... Following a successful two-year campaign of support for the ... Cutlery has announced that it is extending its support ... donated more than $274,000 to Go Red For Women ... $74,000 raised through a 10 percent contribution from the ...
... been proclaimed as "World Glaucoma Day" by glaucoma specialists ... Organization, more than five million people, many of African ... lacked the opportunity to get tested for Earlier Glaucoma ... Dr. Robert Welsh, a Rotarian, a world-renowned Eye Surgeon ...
... insurance store in Mechanicsburg to hold grand opening on ... first pair of health insurance retail stores, Highmark Direct, ... Pennsylvania will celebrate its grand opening at the Silver ... Saturday, March 21. During the grand opening, individuals, families ...
Cached Medicine News:Health News:Weighing the options after life-altering stroke 2Health News:Weighing the options after life-altering stroke 3Health News:Weighing the options after life-altering stroke 4Health News:Better health and prosperity in Europe via improved clinical research 2Health News:Bausch & Lomb Launches Multi-Tiered U.S. Consumer Education Initiative to Raise Awareness of Presbyopia 2Health News:Bausch & Lomb Launches Multi-Tiered U.S. Consumer Education Initiative to Raise Awareness of Presbyopia 3Health News:CUTCO Cutlery Extends Its Support of Go Red For Women 2Health News:Welsh 'Self-Test' to Help Cure Glaucoma on World Glaucoma Day 2Health News:Highmark Retail Store to Celebrate Grand Opening 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: